ProCE Banner Activity

Sustained 72-Week Efficacy With PRM-151 in Myelofibrosis

Slideset Download
Conference Coverage
PRM-151 was well tolerated with observed reductions in bone marrow fibrosis and symptom scores, as well as improved anemia, thrombocytopenia.

Released: December 08, 2015

Expiration: December 06, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Millennium Takeda

Seagen